2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1931

Targeting Cartilage Aging As Osteoarthritis Therapeutics By Drug Repurposing
Abstract Number: 1319

TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Abstract Number: 1320

TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis
Abstract Number: 103

Teaching Musculoskeletal Examination to Internal Medicine Residents in Digital Age
Abstract Number: 1051

Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Abstract Number: 1609

Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Abstract Number: 797

Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Abstract Number: 2256

Temporal Increases in Side Effect Concerns of Osteoporosis Medications Among Women with Previous Fractures
Abstract Number: 895

Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease Due to Granulomatosis with Polyangiitis in the US from 1995-2014
Abstract Number: 827

Temporary Methotrexate Discontinuation for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Abstract Number: 1887

Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
Abstract Number: 580

Tenascin-C, a TLR 4 Endogenous Ligand Levels Are Increased in Ankylosing Spondylitis
Abstract Number: 1345

Tender Joints Have Low Associations with Patient’s Evaluation of Joint Pain and Ultrasound Findings Explored at Joint Level in Patients with Rheumatoid Arthritis
Abstract Number: 1386

Tenosynovitis in the Forefoot at Disease Presentation Is Specific for RA: Results from a Cross-Sectional MRI Study in Early Arthritis
Abstract Number: 320

Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].